Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/181758
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Abrisqueta Costa, Pau | - |
dc.contributor.author | Loscertales, Javier | - |
dc.contributor.author | Terol, Maria José | - |
dc.contributor.author | Ramírez Payer, Ángel | - |
dc.contributor.author | Ortiz, Macarena | - |
dc.contributor.author | Pérez Fernández, Inmaculada | - |
dc.contributor.author | Cuellar García, Carolina | - |
dc.contributor.author | Fernández de la Mata, Margarita | - |
dc.contributor.author | Rodríguez Fernández, Alicia | - |
dc.contributor.author | Lario, Ana | - |
dc.contributor.author | Delgado, Julio | - |
dc.contributor.author | Godoy, Ana | - |
dc.contributor.author | Arguiñano Pérez, José Mª | - |
dc.contributor.author | Berruezo, Mª José | - |
dc.contributor.author | Oliveira Ramos, Ana Carla | - |
dc.contributor.author | Hernández Rivas, José Ángel | - |
dc.contributor.author | García Malo, Maria Dolores | - |
dc.contributor.author | Medina, Ángeles | - |
dc.contributor.author | García Martin, Paloma | - |
dc.contributor.author | Osorio, Santiago | - |
dc.contributor.author | Baltasar, Patricia | - |
dc.contributor.author | Fernández Zarzoso, Miguel | - |
dc.contributor.author | Marco, Fernando | - |
dc.contributor.author | Vidal Manceñido, Mª Jesús | - |
dc.contributor.author | Smucler Simonovich, Alicia Susana | - |
dc.contributor.author | López Rubio, Montserrat | - |
dc.contributor.author | Jarque, Isidro | - |
dc.contributor.author | Suarez Cabrera, Alexia | - |
dc.contributor.author | Fernández Álvarez, Rubén | - |
dc.contributor.author | Lancharro Anchel, Aima | - |
dc.contributor.author | Ríos, Eduardo | - |
dc.contributor.author | Losada Castillo, María del Carmen | - |
dc.contributor.author | Pérez Persona, Ernesto | - |
dc.contributor.author | García Muñoz, Ricardo | - |
dc.contributor.author | Ramos, Rafael | - |
dc.contributor.author | Yáñez, Lucrecia | - |
dc.contributor.author | Bello, José Luis | - |
dc.contributor.author | Loriente, Cristina | - |
dc.contributor.author | Acha, Daniel | - |
dc.contributor.author | Villanueva, Miguel | - |
dc.date.accessioned | 2021-12-13T11:58:01Z | - |
dc.date.available | 2021-12-13T11:58:01Z | - |
dc.date.issued | 2021-08-01 | - |
dc.identifier.issn | 2152-2669 | - |
dc.identifier.uri | http://hdl.handle.net/2445/181758 | - |
dc.description.abstract | Background: Ibrutinib demonstrated remarkable efficacy and favorable tolerability in patients with untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including those with high-risk genetic alterations. The IBRORS-CLL study assessed the characteristics, clinical management and outcome of CLL patients receiving ibrutinib in routine clinical practice in Spain. Patients: Observational, retrospective, multicenter study in CLL patients who started single-agent ibrutinib as first-line treatment or at first or second relapse between January 2016 and January 2019. Results: A total of 269 patients were included (median age: 70.9 years; cardiovascular comorbidity: 55.4%, including hypertension [47.6%] and atrial fibrillation [AF] [7.1%]). Overall, 96.7% and 69% of patients underwent molecular testing for del(17p)/TP53 mutation and IGHV mutation status. High-risk genetic features included unmutated IGHV (79%) and del(17p)/TP53 mutation (first-line: 66.3%; second-line: 23.1%). Overall, 84 (31.2%) patients received ibrutinib as first-line treatment, and it was used as second- and third-line therapy in 121 (45.0%) and 64 (23.8%) patients. The median progression-free survival and overall survival were not reached irrespective of del(17p)/TP53, or unmutated IGHV. Common grade ≥3 adverse events were infections (12.2%) and bleeding (3%). Grade ≥3 AF occurred in 1.5% of patients. Conclusion: This real-world study shows that single-agent ibrutinib is an effective therapy for CLL, regardless of age and high-risk molecular features, consistent with clinical trials. Additionally, single-agent ibrutinib was well tolerated, with a low rate of cardiovascular events. This study also emphasized a high molecular testing rate of del(17p)/TP53 mutation and IGHV mutation status in clinical practice according to guideline recommendations. | - |
dc.format.extent | 15 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier BV | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.clml.2021.07.022 | - |
dc.relation.ispartof | Clinical Lymphoma Myeloma and Leukemia, 2021, vol. 21, num. 12, p. e985-e999 | - |
dc.relation.uri | https://doi.org/10.1016/j.clml.2021.07.022 | - |
dc.rights | cc by (c) Abrisqueta Costa, Pau et al, 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Leucèmia limfocítica crònica | - |
dc.subject.classification | Proteïnes quinases | - |
dc.subject.other | Chronic lymphocytic leukemia | - |
dc.subject.other | Protein kinases | - |
dc.title | Real-world characteristics and outcome of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC Study) | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-12-10T09:35:47Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34511320 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PIIS2152265021003037.pdf | 995.39 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License